Exact sciences corporation stock.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ... Nov 9, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...

EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. EXAS Stock Performance. USD USD; Previous close: 64: 64: Day range: 62.76 - 67.0362.76 - 67.03Year range: 43 - 100

Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...

Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Exact Sciences Corp. historical stock charts and prices, analyst ratings, financials, and today's real-time EXAS stock price.View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main …

Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%.

Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Adjusted EBITDA for the three and six months ended June 30, 2021 has been updated accordingly for comparative purposes. Of the $64.5 million and $60.8 million incurred for the three months ended June 30, 2022 and 2021, $56.4 million and $53.9 million is related to stock-based compensation, respectively, and $8.1 million and $6.9 million is ...Exact Sciences (EXAS) stock is on the rise Friday following news that Guardant Health's (GH) clinical trial didn't go as well as expected. GH is pushing EXAS higher today Source: Shutterstock Exact Sciences (NASDAQ:EXAS) stock is on the ris...

Shares of Exact Sciences ( EXAS 0.93%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...Feb 21, 2023 · MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022. SWAV stock has gained 41.4% so far this year. ShockWave Medical delivered an earnings surprise of 180.1%, on average, in the last four quarters. McKesson’s earnings per share estimates increased ...Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and commercializes diagnostic tests for cancer and other diseases. See real-time data, market cap, key data and news of EXAS on Nasdaq.Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more. Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ...

Exact Sciences ( NASDAQ: EXAS) said that its next-generation Cologuard screening test for colon cancer showed better cancer specificity and sensitivity compared to the currently marketed test ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Stocks Exact Sciences Corp Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...

Find real-time EXAS - Exact Sciences Corp stock quotes, company profile, news and forecasts from CNN Business.

07-Sept-2023 ... Yet, escalating expenses and competition are major downsides. The stock carries a Zacks Rank #3 (Hold) at present. The Exact Sciences team is ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...Sep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. Exact Sciences Corporation (EXAS.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Exact Sciences Corporation ...May 9, 2023 · MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022. A high-level overview of Exact Sciences Corporation (EXAS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment …Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...13-Mar-2021 ... ... CORP ,INCY, BMY, IONIS PHARMACEUTICALS INC ,IONS, EXPERIENCE INVESTMENT CORP-A ,EXPC, ALIBABA GROUP HOLDING-SP ADR ,BABA, ACCOLADE INC ,ACCD ...

Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued.Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings report, analyst report, research reports and more. The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days.. Most of that value climb came yesterday, with the ...Instagram:https://instagram. jfk 50 cent piece 1964namibian stock exchange priceswhat is a buy ratingquarter worth a lot of money Stock Information · Financial Information · SEC Filings · Quarterly Results ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719. Powered By ...FDA approves Cologuard and Exact Sciences receives proposed coverage memorandum from the Centers for Medicare and Medicaid Services (CMS), the first time FDA and CMS simultaneously reviewed a medical device as part of the parallel review pilot program. Mayo Clinic becomes first healthcare system to offer Cologuard. October 2014 how much is a bar of gold worth todaybest platform for futures 02-Nov-2023 ... On today's stock market, EXAS stock sank 1.7% to 62.46. Is EXAS Stock Nearing Profitability? Overall, Exact Sciences posted no earnings on ...Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer diagnostics, and we are currently working to develop additional tests, with the goal of bond ladder Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01.Get the latest news and real-time alerts from Exact Sciences Corporation (EXAS) stock at Seeking Alpha. ... EXAS Exact Sciences Corporation. Latest News. Follow $65.82-0.17 (-0.26%) ...Nov 9, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...